Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Apr;35(4):386–394. doi: 10.1111/j.1365-2125.1993.tb04155.x

Human studies on abecarnil a new beta-carboline anxiolytic: safety, tolerability and preliminary pharmacological profile.

T Duka 1, B Schütt 1, W Krause 1, R Dorow 1, S McDonald 1, K Fichte 1
PMCID: PMC1381549  PMID: 8097921

Abstract

1. Abecarnil (isopropyl-6-benzyloxy-4-methoxymethyl-beta-carboline-3-carboxylate), a beta-carboline with high affinity for benzodiazepine receptors, was tested in healthy male subjects; single doses of abecarnil were given in five dosage levels (1 mg, 5 mg, 10 mg, 20 mg, 40 mg) and in a multiple dose study in four dosage levels (15 mg, 30 mg, 60 mg, 90 mg day-1) for 7 days. On two days following multiple dose treatment, placebo was given in single-blind conditions (follow-up). In each dosage level, in both studies drug was given to 10 subjects (7: verum, 3: placebo). 2. Safety and tolerability were evaluated by changes in vital signs, incidence and severity of adverse reactions and biochemical and haematological screening. Drug effects were estimated utilizing a bipolar visual analogue scale (poles: 'sleepy'-'alert') and a psychomotor task, the digit symbol substitution task. The pharmacokinetics of single and multiple doses were also determined in the multiple dose study. 3. Abecarnil was generally well tolerated. In the single dose study the most frequently reported side effects associated with abecarnil at high doses (20 and 40 mg) were dizziness, unsteady gait, and lack of concentration. A decrement in performance on the digit symbol substitution task was also observed in the two high dosage groups 20 mg and 40 mg. Evaluation of visual analogue scale ratings did not reveal a sedative effect even at higher doses. 4. In the multiple dose study the most frequently reported side effects during the treatment period were dizziness, unsteady gait, and lack of concentration.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
386

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Al-Khudhairi D., Whitwam J. G., Chakrabarti M. K., Askitopoulou H., Grundy E. M., Powrie S. Haemodynamic effects of midazolam and thiopentone during induction of anaesthesia for coronary artery surgery. Br J Anaesth. 1982 Aug;54(8):831–835. doi: 10.1093/bja/54.8.831. [DOI] [PubMed] [Google Scholar]
  2. Ballenger J. C., McDonald S., Noyes R., Rickels K., Sussman N., Woods S., Patin J., Singer J. The first double-blind, placebo-controlled trial of a partial benzodiazepine agonist abecarnil (ZK 112-119) in generalized anxiety disorder. Psychopharmacol Bull. 1991;27(2):171–179. [PubMed] [Google Scholar]
  3. Bond A., Lader M., Shrotriya R. Comparative effects of a repeated dose regime of diazepam and buspirone on subjective ratings, psychological tests and the EEG. Eur J Clin Pharmacol. 1983;24(4):463–467. doi: 10.1007/BF00609887. [DOI] [PubMed] [Google Scholar]
  4. Braestrup C., Nielsen M., Olsen C. E. Urinary and brain beta-carboline-3-carboxylates as potent inhibitors of brain benzodiazepine receptors. Proc Natl Acad Sci U S A. 1980 Apr;77(4):2288–2292. doi: 10.1073/pnas.77.4.2288. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Dommisse C. S., Hayes P. E. Current concepts in clinical therapeutics: anxiety disorders, Part 2. Clin Pharm. 1987 Mar;6(3):196–215. [PubMed] [Google Scholar]
  6. Dorow R., Duka T., Höller L., Sauerbrey N. Clinical perspectives of beta-carbolines from first studies in humans. Brain Res Bull. 1987 Sep;19(3):319–326. doi: 10.1016/0361-9230(87)90100-6. [DOI] [PubMed] [Google Scholar]
  7. Dorow R., Horowski R., Paschelke G., Amin M. Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors. Lancet. 1983 Jul 9;2(8341):98–99. doi: 10.1016/s0140-6736(83)90076-4. [DOI] [PubMed] [Google Scholar]
  8. Duka T., Goerke D., Dorow R., Höller L., Fichte K. Human studies on the benzodiazepine receptor antagonist beta-carboline ZK 93 426: antagonism of lormetazepam's psychotropic effects. Psychopharmacology (Berl) 1988;95(4):463–471. doi: 10.1007/BF00172956. [DOI] [PubMed] [Google Scholar]
  9. Duka T., Stephens D. N., Krause W., Dorow R. Human studies on the benzodiazepine receptor antagonist beta-carboline ZK 93,426: preliminary observations on psychotropic activity. Psychopharmacology (Berl) 1987;93(4):421–427. doi: 10.1007/BF00207229. [DOI] [PubMed] [Google Scholar]
  10. Greenblatt D. J., Shader R. I. Dependence, tolerance, and addiction to benzodiazepines: clinical and pharmacokinetic considerations. Drug Metab Rev. 1978;8(1):13–28. doi: 10.3109/03602537808993775. [DOI] [PubMed] [Google Scholar]
  11. Krause W., Schütt B., Duka T. Pharmacokinetics and acute toleration of the beta-carboline derivative abecarnil in man. Arzneimittelforschung. 1990 May;40(5):529–532. [PubMed] [Google Scholar]
  12. Linnoila M., Erwin C. W., Brendle A., Simpson D. Psychomotor effects of diazepam in anxious patients and healthy volunteers. J Clin Psychopharmacol. 1983 Apr;3(2):88–96. [PubMed] [Google Scholar]
  13. Löscher W., Hönack D., Scherkl R., Hashem A., Frey H. H. Pharmacokinetics, anticonvulsant efficacy and adverse effects of the beta-carboline abecarnil, a novel ligand for benzodiazepine receptors, after acute and chronic administration in dogs. J Pharmacol Exp Ther. 1990 Nov;255(2):541–548. [PubMed] [Google Scholar]
  14. Petersen E. N. DMCM: a potent convulsive benzodiazepine receptor ligand. Eur J Pharmacol. 1983 Oct 14;94(1-2):117–124. doi: 10.1016/0014-2999(83)90448-x. [DOI] [PubMed] [Google Scholar]
  15. Petersen E. N., Jensen L. H. Proconflict effect of benzodiazepine receptor inverse agonists and other inhibitors of GABA function. Eur J Pharmacol. 1984 Aug 3;103(1-2):91–97. doi: 10.1016/0014-2999(84)90193-6. [DOI] [PubMed] [Google Scholar]
  16. Potier M. C., Prado de Carvalho L., Dodd R. H., Besselievre R., Rossier J. In vivo binding of beta-carbolines in mice: regional differences and correlation of occupancy to pharmacological effects. Mol Pharmacol. 1988 Aug;34(2):124–128. [PubMed] [Google Scholar]
  17. Rao S., Sherbaniuk R. W., Prasad K., Lee S. J., Sproule B. J. Cardiopulmonary effects of diazepam. Clin Pharmacol Ther. 1973 Mar-Apr;14(2):182–189. doi: 10.1002/cpt1973142182. [DOI] [PubMed] [Google Scholar]
  18. Seitz W., Hempelmann G., Piepenbrock S. Zur kardiovaskulären Wirkung von Flunitrazepam (Rohypnol, RO-5-4200). Anaesthesist. 1977 May;26(5):249–256. [PubMed] [Google Scholar]
  19. Stephens D. N., Kehr W. Beta-carbolines can enhance or antagonize the effects of punishment in mice. Psychopharmacology (Berl) 1985;85(2):143–147. doi: 10.1007/BF00428403. [DOI] [PubMed] [Google Scholar]
  20. Stephens D. N., Schneider H. H., Kehr W., Andrews J. S., Rettig K. J., Turski L., Schmiechen R., Turner J. D., Jensen L. H., Petersen E. N. Abecarnil, a metabolically stable, anxioselective beta-carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther. 1990 Apr;253(1):334–343. [PubMed] [Google Scholar]
  21. Turski L., Stephens D. N., Jensen L. H., Petersen E. N., Meldrum B. S., Patel S., Hansen J. B., Löscher W., Schneider H. H., Schmiechen R. Anticonvulsant action of the beta-carboline abecarnil: studies in rodents and baboon, Papio papio. J Pharmacol Exp Ther. 1990 Apr;253(1):344–352. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES